JAC-Antimicrobial Resistance

Scope & Guideline

Advancing the Fight Against Antimicrobial Resistance

Introduction

Immerse yourself in the scholarly insights of JAC-Antimicrobial Resistance with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN-
PublisherOXFORD UNIV PRESS
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationJAC-ANTIMICROB RESIS / JAC-Antimicrob. Resist.
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressGREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND

Aims and Scopes

The journal 'JAC-Antimicrobial Resistance' focuses on addressing the challenges of antimicrobial resistance (AMR) through a multidisciplinary approach, emphasizing research that informs clinical practice, public health policy, and stewardship initiatives.
  1. Antimicrobial Resistance Mechanisms:
    Research exploring the genetic and phenotypic mechanisms underlying resistance in various pathogens, including Gram-negative and Gram-positive bacteria.
  2. Antimicrobial Stewardship Practices:
    Studies evaluating the effectiveness of antimicrobial stewardship programs across different healthcare settings, aiming to improve prescribing practices and reduce resistance.
  3. Clinical Outcomes in Infections:
    Investigations into the clinical effectiveness of various antimicrobial therapies, including novel agents and combinations, particularly in resistant infections.
  4. Diagnostic Innovations:
    Research on new diagnostic techniques for rapid identification of resistant pathogens and susceptibility testing to guide treatment decisions.
  5. Global Perspectives on AMR:
    Studies that provide insights into the burden of AMR across different regions, including low- and middle-income countries, and the impact of local practices on resistance patterns.
  6. Public Awareness and Education:
    Exploration of public knowledge and attitudes towards AMR and antibiotic use, aiming to inform educational strategies and policy interventions.
Recent publications in 'JAC-Antimicrobial Resistance' have highlighted several emerging themes that reflect the current trends and priorities in the field of antimicrobial resistance research.
  1. Genomic Surveillance of Resistance:
    There is a growing emphasis on genomic studies that track the emergence and spread of resistance genes among pathogens, providing insights into transmission dynamics and potential interventions.
  2. Innovative Therapeutic Approaches:
    Research into novel antimicrobial agents and combination therapies is on the rise, particularly those targeting multidrug-resistant organisms and utilizing adjunctive therapies such as phage therapy.
  3. AI and Machine Learning in AMR:
    The integration of artificial intelligence and machine learning in predicting resistance patterns and optimizing treatment strategies is emerging as a key area of interest.
  4. Global AMR Surveillance Initiatives:
    Increased focus on global surveillance efforts to monitor AMR trends and inform public health policies, particularly in low-resource settings.
  5. Patient-Centered Stewardship Strategies:
    There is a trend towards investigating the impact of patient education and engagement on antimicrobial stewardship outcomes, aiming to enhance adherence to guidelines and reduce over-prescribing.

Declining or Waning

As the field of antimicrobial resistance research evolves, certain themes have seen a decline in focus within the journal. This shift may reflect changing priorities in research funding and public health initiatives.
  1. Traditional Antibiotic Efficacy Studies:
    There has been a noticeable decrease in studies solely focusing on the efficacy of traditional antibiotics against common pathogens, as more attention is now directed towards resistance mechanisms and novel therapies.
  2. Single-Agent Studies:
    Research focusing on the effectiveness of single-agent antibiotics is waning, with a shift towards combination therapies and innovative treatment approaches to overcome resistance.
  3. Environmental AMR Studies:
    While environmental aspects of AMR are still relevant, the frequency of publications specifically addressing environmental reservoirs of resistance has decreased in favor of clinical and translational research.
  4. Non-Clinical Perspectives:
    Previously common themes addressing the sociocultural implications of AMR and non-clinical perspectives are less prevalent, as the focus shifts towards immediate clinical applications and outcomes.

Similar Journals

JOURNAL OF CLINICAL MICROBIOLOGY

Navigating the Complexities of Microbial Pathogens
Publisher: AMER SOC MICROBIOLOGYISSN: 0095-1137Frequency: 12 issues/year

JOURNAL OF CLINICAL MICROBIOLOGY, published by the American Society for Microbiology, stands as a premier resource for researchers and professionals in the field of medical microbiology. With an illustrious history dating back to 1975, this journal has consistently provided high-impact research, reflecting its status in the Q1 category among microbiology (medical) journals, and an impressive Scopus rank of 14 out of 140, placing it in the 90th percentile. The journal's commitment to unveiling foundational and innovative studies greatly contributes to understanding human health challenges posed by microbial pathogens. Researchers can expect rigorous peer-reviewed articles that cover a spectrum of topics, from diagnostic methods to clinical epidemiology, fostering a deeper understanding of microbiology's role in healthcare. While this journal does not offer open access options, its substantial impact factor underscores its relevance in shaping the conversation in clinical microbiology. The JOURNAL OF CLINICAL MICROBIOLOGY is indispensable for anyone dedicated to advancing their knowledge and practical skills in microbiology.

Antibiotics-Basel

Pioneering discoveries in antibiotic management and resistance.
Publisher: MDPIISSN: 2079-6382Frequency: 12 issues/year

Antibiotics-Basel is a prestigious multidisciplinary journal published by MDPI, dedicated to advancing the field of antibiotic research and management. Since its inception in 2012 as an Open Access publication, the journal has established itself as a vital resource for researchers and professionals, offering an accessible platform for the dissemination of innovative findings in Biochemistry, Infectious Diseases, Microbiology, and Pharmacology. With a solid impact in its category, Antibiotics-Basel holds a Q1 ranking in critical areas such as Pharmacology and Pharmacology, Toxicology and Pharmaceutics, making it an influential journal in its field. The journal publishes high-quality research articles, reviews, and communications that are essential for advancing our understanding of antibiotic mechanisms, resistance, and therapeutic applications. Researchers are invited to submit their manuscript to contribute to this growing body of knowledge and collaborate in the fight against antibiotic resistance and infectious diseases.

Expert Review of Anti-Infective Therapy

Pioneering Reviews in Infectious Disease Therapy
Publisher: TAYLOR & FRANCIS LTDISSN: 1478-7210Frequency: 12 issues/year

Expert Review of Anti-Infective Therapy, published by Taylor & Francis Ltd, is a leading journal in the field of infectious diseases, microbiology, and virology, boasting an impressive impact factor and ranking in the Q1 category across multiple disciplines. With an ISSN of 1478-7210 and E-ISSN 1744-8336, this journal has become a vital resource for researchers, professionals, and students aiming to advance their understanding of anti-infective therapies. Since its inception in 2003, the journal has provided critical insights, evidence-based reviews, and forward-thinking perspectives that contribute significantly to the ongoing efforts in combating infectious diseases. As of 2023, it ranks #36 out of 344 in Medicine/Infectious Diseases and maintains high percentiles in various other categories, reflecting its influence and reach within the scientific community. Although not an Open Access journal, its rich content is delivered through various academic libraries, sustaining its commitment to disseminating knowledge in the face of global health challenges. For those committed to innovation in the field, the Expert Review of Anti-Infective Therapy offers a platform that blends thorough research with practical applications, making significant strides in the fight against infectious pathogens.

Infectious Diseases Now

Innovating solutions for today's health crises.
Publisher: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIERISSN: 2666-9927Frequency: 8 issues/year

Infectious Diseases Now is a premier academic journal dedicated to the evolving field of infectious diseases, published by Elsevier France - Éditions Scientifiques Médicales Elsevier. With an ISSN of 2666-9927 and an E-ISSN of 2666-9919, this journal stands at the forefront of disseminating critical research and clinical insights from 2021 to 2024. The journal's commitment to open access means that groundbreaking studies are readily available to researchers, healthcare professionals, and students, fostering a collaborative approach to tackling global health challenges. As evidenced by its Q2 quartile ranking in the 2023 Scopus category of Infectious Diseases, and its impressive position within the top 25% of its field, Infectious Diseases Now serves as an essential resource for those involved in the study and management of infectious diseases. By publishing high-quality research, case studies, and reviews, the journal plays a pivotal role in advancing knowledge and improving patient care in this vital area of medicine.

BMC INFECTIOUS DISEASES

Transforming public health through rigorous research.
Publisher: BMCISSN: Frequency: 1 issue/year

BMC Infectious Diseases is a premier open-access journal published by BMC in the United Kingdom, dedicated to the field of infectious diseases. Established in 2001, this journal has been at the forefront of disseminating high-quality, peer-reviewed research, contributing significantly to the global understanding of infectious pathogens and their impact on public health. With a 2023 Scopus ranking of #100 out of 344 in the Medicine - Infectious Diseases category, and a notable Q1 quartile classification, it stands as a vital resource for researchers and professionals alike. Authors benefit from the journal's broad reach and visibility, ensuring their work is accessible to a wide audience. Access options are fully open, allowing for seamless dissemination of knowledge in the ongoing battle against infectious diseases. With an established history of publishing groundbreaking studies, BMC Infectious Diseases plays a crucial role in addressing critical issues and advancing research in the ever-evolving landscape of infectious diseases.

GMS Hygiene and Infection Control

Connecting research and practice for optimal health outcomes.
Publisher: GERMAN MEDICAL SCIENCE-GMSISSN: 2196-5226Frequency: 1 issue/year

GMS Hygiene and Infection Control is a leading open access journal dedicated to advancing knowledge and research in the fields of hygiene, infection control, and public health. Published by GERMAN MEDICAL SCIENCE-GMS, this journal has been offering unrestricted access to its rich repository of scholarly articles since 2013, making significant contributions to the global discourse on infection prevention and control strategies. With its commitment to promoting high-quality research, GMS Hygiene and Infection Control is a vital resource for researchers, healthcare professionals, and students engaged in the pursuit of best practices for improving health outcomes. The journal is built upon a foundation of rigorous peer review and aims to disseminate innovative findings that address current challenges in hygiene and infection control, thereby enhancing clinical practices and public health policies worldwide.

CLINICAL MICROBIOLOGY AND INFECTION

Pioneering Research in Infectious Diseases
Publisher: ELSEVIER SCI LTDISSN: 1198-743XFrequency: 12 issues/year

CLINICAL MICROBIOLOGY AND INFECTION is a leading journal published by Elsevier Science Ltd, dedicated to advancing the field of infectious diseases and clinical microbiology. With its ISSN 1198-743X and E-ISSN 1469-0691, this esteemed journal has maintained its influential presence since 1995, showcasing high-impact research that addresses critical issues in the diagnosis, treatment, and prevention of infections. Ranked in the Q1 quartile for Infectious Diseases, Medicine (miscellaneous), and Microbiology (medical) categories, and boasting impressive Scopus rankings of #12 and #7 respectively, it sits at the forefront of scientific inquiry in these disciplines. Although it is not an Open Access journal, it provides comprehensive access options for institutions and individuals, ensuring the dissemination of vital research findings. As the field of clinical microbiology continues to evolve, CLINICAL MICROBIOLOGY AND INFECTION remains an essential resource for researchers, clinicians, and students aiming to stay informed on the latest developments and breakthroughs in understanding infectious diseases.

Infection and Drug Resistance

Illuminating the path to effective therapeutic interventions.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1178-6973Frequency: 1 issue/year

Infection and Drug Resistance, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to the critical fields of infectious diseases and pharmacology. Since its establishment in 2008, this journal has emerged as a vital resource for researchers, professionals, and students alike, offering thorough insights into the mechanisms of drug resistance and the effectiveness of various therapeutic interventions. With an impressive 2023 impact factor placing it in the Q2 category across multiple relevant disciplines, including Infectious Diseases and Pharmacology, it serves as a significant platform for high-quality research dissemination. Infection and Drug Resistance aims to foster a deeper understanding of the evolving challenges in managing infectious diseases and enhancing drug efficacy, contributing to the global discourse on public health. The journal's commitment to open access ensures that vital knowledge is readily available to promote broader scholarly engagement and innovation.

ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA

Shaping the future of microbiological inquiry.
Publisher: AKADEMIAI KIADO ZRTISSN: 1217-8950Frequency: 4 issues/year

ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA is a distinguished academic journal published by AKADEMIAI KIADO ZRT, focusing on significant advancements in the fields of microbiology, immunology, and infectious diseases. Established in 1994, this journal serves as a vital platform for researchers, professionals, and students keen on exploring the complexities of microbial interactions and immune responses. With a current Impact Factor reflecting its rank within the Q3 categories for Immunology, Microbiology, and Infectious Diseases, it retains a critical position in disseminating innovative research. Although not open access, the journal provides extensive insights disseminated through various academic databases, ensuring a broad reach within the scholarly community. Its convergence over three decades indicates a robust commitment to excellence in scientific inquiry and knowledge sharing. As it moves towards the future, ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA continues to uphold its legacy of fostering collaborative research initiatives that contribute to the understanding and treatment of microbial diseases globally.

Annals of Clinical Microbiology and Antimicrobials

Fostering innovation in the fight against infectious diseases.
Publisher: BMCISSN: Frequency: 1 issue/year

Annals of Clinical Microbiology and Antimicrobials, published by BMC, is a leading open-access journal that has been fostering scientific discourse in the fields of microbiology and infectious diseases since its inception in 2002. With an established reputation for excellence, this journal is positioned in the prestigious Q1 category across multiple disciplines, including Infectious Diseases, Medicine (miscellaneous), and Medical Microbiology as of 2023. This journal serves as a vital platform for researchers, healthcare professionals, and students, promoting the latest advancements in clinical microbiology and antimicrobial research. Access to its invaluable content is open to all, reflecting the commitment to disseminate knowledge universally. The Annals of Clinical Microbiology and Antimicrobials is based in the United Kingdom and continues to pave the way for innovation and discussions that shape the future of clinical practices in microbiology.